Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

Seven Fleet Capital Management LP boosted its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 302.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,228,144 shares of the company’s stock after purchasing an additional 2,425,484 shares during the quarter. Tango Therapeutics comprises about 15.8% of Seven Fleet Capital Management LP’s holdings, making the stock its 2nd biggest position. Seven Fleet Capital Management LP owned 1.91% of Tango Therapeutics worth $95,661,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allworth Financial LP bought a new position in shares of Tango Therapeutics during the 2nd quarter worth about $35,000. Global Retirement Partners LLC acquired a new position in Tango Therapeutics during the 4th quarter worth approximately $35,000. Dynamic Technology Lab Private Ltd raised its stake in Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after buying an additional 15,037 shares during the period. Legal & General Group Plc boosted its holdings in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after acquiring an additional 1,640 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $40,000. 78.99% of the stock is owned by institutional investors.

Insider Buying and Selling at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wedbush boosted their price objective on Tango Therapeutics from $19.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. HC Wainwright lifted their price target on shares of Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Jefferies Financial Group upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $27.00 to $60.00 in a research note on Thursday, June 25th. Leerink Partners upped their price objective on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Finally, JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics in a report on Wednesday, July 15th. They set an “overweight” rating and a $46.00 price objective for the company. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tango Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $43.46.

Tango Therapeutics Trading Up 2.8%

Shares of Tango Therapeutics stock opened at $25.47 on Thursday. The company has a market capitalization of $4.29 billion, a P/E ratio of -29.96 and a beta of 1.16. The stock has a fifty day simple moving average of $27.90 and a 200 day simple moving average of $23.04. Tango Therapeutics, Inc. has a 12-month low of $6.25 and a 12-month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts predict that Tango Therapeutics, Inc. will post -1.38 EPS for the current year.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.